RU2017123545A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017123545A3 RU2017123545A3 RU2017123545A RU2017123545A RU2017123545A3 RU 2017123545 A3 RU2017123545 A3 RU 2017123545A3 RU 2017123545 A RU2017123545 A RU 2017123545A RU 2017123545 A RU2017123545 A RU 2017123545A RU 2017123545 A3 RU2017123545 A3 RU 2017123545A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088228P | 2014-12-05 | 2014-12-05 | |
| US62/088,228 | 2014-12-05 | ||
| PCT/US2015/064122 WO2016090329A2 (en) | 2014-12-05 | 2015-12-04 | Antibodies targeting g-protein coupled receptor and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020120613A Division RU2020120613A (ru) | 2014-12-05 | 2015-12-04 | Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017123545A RU2017123545A (ru) | 2019-01-14 |
| RU2017123545A3 true RU2017123545A3 (enExample) | 2019-12-11 |
| RU2725819C2 RU2725819C2 (ru) | 2020-07-06 |
Family
ID=56092679
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020120613A RU2020120613A (ru) | 2014-12-05 | 2015-12-04 | Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения |
| RU2017123545A RU2725819C2 (ru) | 2014-12-05 | 2015-12-04 | Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020120613A RU2020120613A (ru) | 2014-12-05 | 2015-12-04 | Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10590196B2 (enExample) |
| EP (1) | EP3227324A4 (enExample) |
| JP (6) | JP6753851B2 (enExample) |
| KR (2) | KR102602417B1 (enExample) |
| CN (3) | CN107206077B (enExample) |
| AU (3) | AU2015357535B2 (enExample) |
| BR (1) | BR112017011932A8 (enExample) |
| CA (1) | CA2969886A1 (enExample) |
| IL (3) | IL285101B2 (enExample) |
| MX (3) | MX2017007247A (enExample) |
| MY (1) | MY195115A (enExample) |
| PH (1) | PH12017501039A1 (enExample) |
| RU (2) | RU2020120613A (enExample) |
| SA (1) | SA517381664B1 (enExample) |
| SG (2) | SG11201704552TA (enExample) |
| WO (1) | WO2016090329A2 (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3227339B1 (en) | 2014-12-05 | 2021-11-10 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
| KR102602417B1 (ko) * | 2014-12-05 | 2023-11-16 | 메모리얼 슬로안 케터링 캔서 센터 | G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법 |
| RU2767209C2 (ru) | 2015-10-23 | 2022-03-16 | Еурека Терапьютикс, Инк. | Химерные конструкции антитело/т-клеточный рецептор и их применения |
| TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| BR112019011277A2 (pt) | 2016-12-02 | 2019-10-22 | University Of Southern California | polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos. |
| BR112019016204A2 (pt) | 2017-02-07 | 2020-07-07 | Daiichi Sankyo Company, Limited | anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d |
| IL310182A (en) | 2017-04-26 | 2024-03-01 | Eureka Therapeutics Inc ׂ A Delaware Corp | Structures of chimeric antibody/T-cell receptor and uses thereof |
| ES2992909T3 (en) | 2017-08-09 | 2024-12-19 | Juno Therapeutics Inc | Methods and compositions for preparing genetically engineered cells |
| MA49979A (fr) | 2017-08-09 | 2020-06-17 | Juno Therapeutics Inc | Procédés de production de compositions de cellules génétiquement modifiées et compositions associées |
| WO2019051335A1 (en) | 2017-09-07 | 2019-03-14 | Juno Therapeutics, Inc. | METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY |
| TW201927336A (zh) | 2017-10-05 | 2019-07-16 | 日商第一三共股份有限公司 | 細胞毒性ｔ細胞耗竭用組成物 |
| AU2018360801A1 (en) | 2017-11-01 | 2020-05-14 | Celgene Corporation | Process for producing a T cell composition |
| EP3704230B1 (en) | 2017-11-01 | 2024-10-23 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| KR20200116081A (ko) | 2017-12-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포의 투약 및 조절 방법 |
| CN112004824B (zh) | 2017-12-08 | 2024-09-13 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| CN112203680A (zh) | 2017-12-08 | 2021-01-08 | 朱诺治疗学股份有限公司 | 用于细胞疗法的表型标记和相关方法 |
| KR102833956B1 (ko) | 2017-12-08 | 2025-07-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포를 배양하기 위한 무혈청 배지 제형 및 이의 사용 방법 |
| TWI829667B (zh) * | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| SG11202009525VA (en) * | 2018-03-30 | 2020-10-29 | Eureka Therapeutics Inc | Constructs targeting cd22 and uses thereof |
| WO2019210207A2 (en) * | 2018-04-27 | 2019-10-31 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis |
| MX2020012286A (es) * | 2018-05-16 | 2021-04-28 | Janssen Biotech Inc | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. |
| AU2019316647A1 (en) | 2018-08-09 | 2021-02-25 | Juno Therapeutics, Inc. | Methods for assessing integrated nucleic acids |
| CN113474450A (zh) | 2018-08-09 | 2021-10-01 | 朱诺治疗学股份有限公司 | 产生工程化细胞的方法以及所述工程化细胞的组合物 |
| EP3874024A1 (en) | 2018-10-31 | 2021-09-08 | Juno Therapeutics GmbH | Methods for selection and stimulation of cells and apparatus for same |
| AU2019372331A1 (en) | 2018-11-01 | 2021-05-27 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| EP3873937A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| JP7695882B2 (ja) | 2018-11-30 | 2025-06-19 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いた処置のための方法 |
| JP7754722B2 (ja) | 2019-05-01 | 2025-10-15 | ジュノー セラピューティクス インコーポレイテッド | 改変されたｃｄ２４７遺伝子座からキメラ受容体を発現する細胞、関連ポリヌクレオチド、および方法 |
| MA55811A (fr) | 2019-05-01 | 2022-03-09 | Editas Medicine Inc | Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associés |
| AU2020293230A1 (en) | 2019-06-12 | 2022-01-27 | Juno Therapeutics, Inc. | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein |
| AU2020290579A1 (en) | 2019-06-14 | 2021-12-16 | Dana-Farber Cancer Institute, Inc. | Antibodies against MUC1 and methods of use thereof |
| CN114729383A (zh) | 2019-07-02 | 2022-07-08 | 弗莱德哈钦森癌症研究中心 | 重组ad35载体及相关基因疗法改进 |
| CN114174338A (zh) | 2019-07-31 | 2022-03-11 | 豪夫迈·罗氏有限公司 | 与gprc5d结合的抗体 |
| PE20220394A1 (es) | 2019-07-31 | 2022-03-18 | Hoffmann La Roche | Anticuerpos que se fijan a gprc5d |
| EP4017527A1 (en) | 2019-08-22 | 2022-06-29 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| WO2021084050A1 (en) | 2019-10-30 | 2021-05-06 | Juno Therapeutics Gmbh | Cell selection and/or stimulation devices and methods of use |
| EP4069742A1 (en) * | 2019-12-06 | 2022-10-12 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
| AU2021214142A1 (en) | 2020-01-28 | 2022-09-08 | Juno Therapeutics, Inc. | Methods for T cell transduction |
| CA3177604A1 (en) * | 2020-04-17 | 2021-10-21 | Janssen Biotech, Inc. | Biosynthetic glycoprotein populations |
| CN115803824A (zh) | 2020-05-13 | 2023-03-14 | 朱诺治疗学股份有限公司 | 鉴定与临床反应相关的特征的方法及其用途 |
| EP4171616A1 (en) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
| WO2022148370A1 (en) * | 2021-01-05 | 2022-07-14 | Lanova Medicines Development Co., Ltd. | Anti-gprc5d monoclonal antibodies and uses thereof |
| EP4670724A2 (en) | 2021-01-05 | 2025-12-31 | Lanova Medicines Development Co., Ltd. | Monoclonal Anti-GPRC5D Antibodies and Their Uses |
| CA3211163A1 (en) | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
| EP4301755A1 (en) | 2021-03-03 | 2024-01-10 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| EP4314814A1 (en) | 2021-03-22 | 2024-02-07 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
| JP2024511420A (ja) | 2021-03-22 | 2024-03-13 | ジュノー セラピューティクス インコーポレイテッド | ウイルスベクター粒子の効力を評価する方法 |
| EP4334341A2 (en) | 2021-05-06 | 2024-03-13 | Juno Therapeutics GmbH | Methods for stimulating and transducing t cells |
| WO2022247804A1 (zh) * | 2021-05-23 | 2022-12-01 | 上海祥耀生物科技有限责任公司 | 抗gprc5d抗体、其制备方法与用途 |
| TW202334222A (zh) * | 2021-11-05 | 2023-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 結合gprc5d的抗體及其用途 |
| KR20240113514A (ko) | 2021-11-30 | 2024-07-22 | 다이이찌 산쿄 가부시키가이샤 | 프로테아제 분해성 마스크 항체 |
| EP4458851A1 (en) * | 2021-12-31 | 2024-11-06 | Kyinno Biotechnology Co., Ltd. | Anti-gprc5d antibody and use thereof |
| WO2023131328A1 (zh) * | 2022-01-10 | 2023-07-13 | 南京维立志博生物科技有限公司 | 一种抗体及其用途 |
| EP4469563A1 (en) | 2022-01-28 | 2024-12-04 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
| JPWO2023153442A1 (enExample) | 2022-02-09 | 2023-08-17 | ||
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| EP4532695A1 (en) | 2022-05-25 | 2025-04-09 | Celgene Corporation | Methods of manufacturing t cell therapies |
| CA3257679A1 (en) * | 2022-05-27 | 2023-11-30 | Antengene Biologics Limited | NEW ANTI-GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND TO GPRC5D AND CD3, AND THEIR USES |
| KR20250060188A (ko) | 2022-06-30 | 2025-05-07 | 인답타 세라뷰틱스 인코포레이티드 | 조작된 자연 살해(nk) 세포 및 항체 요법의 조합 및 관련 방법 |
| CN119698434A (zh) * | 2022-07-21 | 2025-03-25 | 山东先声生物制药有限公司 | 抗gprc5d纳米抗体及其应用 |
| KR20250047766A (ko) | 2022-08-05 | 2025-04-04 | 주노 쎄러퓨티크스 인코퍼레이티드 | Gprc5d 및 bcma에 특이적인 키메라 항원 수용체 |
| CN120152717A (zh) | 2022-09-08 | 2025-06-13 | 朱诺治疗学股份有限公司 | T细胞疗法和连续或间歇dgk抑制剂给药的组合 |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN121002052A (zh) | 2023-02-03 | 2025-11-21 | C3S2 有限公司 | 用于非病毒生产工程化免疫细胞的方法 |
| WO2024220588A1 (en) | 2023-04-18 | 2024-10-24 | Juno Therapeutics, Inc. | Cytotoxicity assay for assessing potency of therapeutic cell compositions |
| WO2024243365A2 (en) | 2023-05-23 | 2024-11-28 | Juno Therapeutics, Inc. | Activation markers of t cells and method for assessing t cell activation |
| AR133427A1 (es) * | 2023-07-31 | 2025-09-24 | Sanofi Sa | Anticuerpos anti-gprc5d y composiciones |
| WO2025059362A1 (en) | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025134049A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis |
| WO2025134050A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025231408A2 (en) | 2024-05-03 | 2025-11-06 | Janssen Biotech, Inc. | Methods for treating multiple myeloma with car-t cells and bispecific antibodies |
| WO2025231372A2 (en) | 2024-05-03 | 2025-11-06 | Janssen Biotech, Inc. | Methods for treating multiple myeloma with car-t cells and bispecific antibodies |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| EP0804575A1 (en) * | 1994-08-11 | 1997-11-05 | Takeda Chemical Industries, Ltd. | G protein coupled receptor protein, production, and use thereof |
| CN1824777A (zh) * | 1999-09-24 | 2006-08-30 | 索尔瓦药物有限公司 | 新的人g蛋白偶联受体 |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| CA2457496A1 (en) * | 2001-08-20 | 2003-02-27 | Curagen Corporation | Gpcr-like retinoic acid-induced gene 1 protein and nucleic acid |
| US20050019320A1 (en) * | 2001-12-27 | 2005-01-27 | Eiji Sugaru | Remedies for anorexia or lifestyle-related diseases and method of screening the same |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7276372B2 (en) * | 2002-12-20 | 2007-10-02 | Pdl Biopharma, Inc. | Antibodies against GPR64 and uses thereof |
| MXPA05008521A (es) * | 2003-02-13 | 2005-10-20 | Pharmacia Corp | Anticuerpos a c-met para el tratamiento de canceres. |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP5362563B2 (ja) * | 2006-08-03 | 2013-12-11 | アストラゼネカ・アクチエボラーグ | αＶβ６に対する抗体およびその使用 |
| US9512236B2 (en) * | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| JP5840837B2 (ja) | 2007-03-30 | 2016-01-06 | メモリアル スローン−ケタリング キャンサー センター | 養子移入ｔリンパ球における副刺激リガンドの構成性発現 |
| EP2192922A4 (en) * | 2007-09-17 | 2010-09-29 | Univ California | INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES |
| US7947807B2 (en) * | 2007-10-15 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3) |
| JP5808536B2 (ja) | 2007-10-25 | 2015-11-10 | トレリス バイオサイエンス、インク． | 抗ｒｓｖｇタンパク質抗体 |
| MX2010008786A (es) | 2008-02-11 | 2010-12-01 | Curetech Ltd | Anticuerpos monoclonales para tratamiento de tumores. |
| US9217032B2 (en) * | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| CA2806250C (en) * | 2010-07-22 | 2020-09-22 | John W. Schrader | Cross-protective pathogen protection, methods and compositions thereof |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| JO3519B1 (ar) * | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| KR102332790B1 (ko) | 2013-02-15 | 2021-12-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| EP3309248B1 (en) | 2013-05-29 | 2021-06-09 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| EP3164417A1 (en) * | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| EP3227339B1 (en) | 2014-12-05 | 2021-11-10 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
| KR102602417B1 (ko) * | 2014-12-05 | 2023-11-16 | 메모리얼 슬로안 케터링 캔서 센터 | G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법 |
| RU2767209C2 (ru) * | 2015-10-23 | 2022-03-16 | Еурека Терапьютикс, Инк. | Химерные конструкции антитело/т-клеточный рецептор и их применения |
| AU2017244108B2 (en) | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US11768203B2 (en) * | 2016-03-31 | 2023-09-26 | University Of Southern California | Highly sensitive and specific luciferase based reporter assay for antigen detection |
| EP3873937A2 (en) * | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
-
2015
- 2015-12-04 KR KR1020177018387A patent/KR102602417B1/ko active Active
- 2015-12-04 SG SG11201704552TA patent/SG11201704552TA/en unknown
- 2015-12-04 BR BR112017011932A patent/BR112017011932A8/pt active Search and Examination
- 2015-12-04 EP EP15865989.6A patent/EP3227324A4/en active Pending
- 2015-12-04 MY MYPI2017000851A patent/MY195115A/en unknown
- 2015-12-04 KR KR1020237038827A patent/KR20230159637A/ko not_active Ceased
- 2015-12-04 SG SG10201913937QA patent/SG10201913937QA/en unknown
- 2015-12-04 RU RU2020120613A patent/RU2020120613A/ru unknown
- 2015-12-04 CN CN201580075556.XA patent/CN107206077B/zh active Active
- 2015-12-04 RU RU2017123545A patent/RU2725819C2/ru active
- 2015-12-04 WO PCT/US2015/064122 patent/WO2016090329A2/en not_active Ceased
- 2015-12-04 MX MX2017007247A patent/MX2017007247A/es unknown
- 2015-12-04 JP JP2017529742A patent/JP6753851B2/ja active Active
- 2015-12-04 IL IL285101A patent/IL285101B2/en unknown
- 2015-12-04 CN CN202110535457.2A patent/CN113429484A/zh active Pending
- 2015-12-04 AU AU2015357535A patent/AU2015357535B2/en active Active
- 2015-12-04 IL IL307767A patent/IL307767A/en unknown
- 2015-12-04 CN CN202110535420.XA patent/CN113429482A/zh active Pending
- 2015-12-04 CA CA2969886A patent/CA2969886A1/en active Pending
-
2017
- 2017-06-04 IL IL252646A patent/IL252646B/en unknown
- 2017-06-05 MX MX2022009463A patent/MX2022009463A/es unknown
- 2017-06-05 SA SA517381664A patent/SA517381664B1/ar unknown
- 2017-06-05 PH PH12017501039A patent/PH12017501039A1/en unknown
- 2017-06-05 MX MX2022001878A patent/MX2022001878A/es unknown
- 2017-06-05 US US15/614,290 patent/US10590196B2/en active Active
-
2019
- 2019-12-31 US US16/732,022 patent/US11566071B2/en active Active
- 2019-12-31 US US16/731,973 patent/US20200123249A1/en not_active Abandoned
-
2020
- 2020-05-07 JP JP2020081773A patent/JP7027482B2/ja active Active
- 2020-08-10 AU AU2020217320A patent/AU2020217320A1/en not_active Abandoned
- 2020-08-24 JP JP2020140643A patent/JP2020191900A/ja not_active Withdrawn
-
2022
- 2022-01-11 JP JP2022002183A patent/JP2022044638A/ja not_active Withdrawn
- 2022-05-19 JP JP2022082303A patent/JP2022103382A/ja not_active Withdrawn
- 2022-12-22 US US18/145,254 patent/US20240076370A1/en active Pending
-
2023
- 2023-11-21 AU AU2023270242A patent/AU2023270242A1/en not_active Abandoned
-
2024
- 2024-03-06 JP JP2024033776A patent/JP2024053016A/ja active Pending
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20210324 |